home / stock / nrbo / nrbo quote
Last: | $3.74 |
---|---|
Change Percent: | 0.27% |
Open: | $3.67 |
Close: | $3.73 |
High: | $3.7997 |
Low: | $3.6 |
Volume: | 18,126 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.74 | $3.67 | $3.73 | $3.7997 | $3.6 | 18,126 | 05-03-2024 |
$3.73 | $3.67 | $3.73 | $3.73 | $3.55 | 14,904 | 05-02-2024 |
$3.68 | $3.43 | $3.68 | $3.68 | $3.35 | 60,029 | 05-01-2024 |
$3.25 | $3.37 | $3.25 | $3.4499 | $3.245 | 42,244 | 04-30-2024 |
$3.23 | $3.2299 | $3.23 | $3.23 | $3.1 | 12,277 | 04-29-2024 |
$3.14 | $3.06 | $3.14 | $3.14 | $3 | 17,307 | 04-26-2024 |
$3.06 | $3.05 | $3.06 | $3.16 | $3.0325 | 1,823 | 04-25-2024 |
$3.1 | $2.99 | $3.1 | $3.4999 | $2.99 | 39,253 | 04-24-2024 |
$3.02 | $3.1 | $3.02 | $3.19 | $2.99 | 42,194 | 04-23-2024 |
$3.12 | $3.26 | $3.12 | $3.3 | $3.08 | 23,389 | 04-22-2024 |
$3.37 | $3.49 | $3.37 | $3.49 | $3.26 | 20,562 | 04-19-2024 |
$3.44 | $3.59 | $3.44 | $3.59 | $3.3534 | 22,788 | 04-18-2024 |
$3.46 | $3.69 | $3.46 | $3.69 | $3.46 | 11,485 | 04-17-2024 |
$3.4 | $3.615 | $3.4 | $3.615 | $3.33 | 12,946 | 04-16-2024 |
$3.53 | $3.61 | $3.53 | $3.73 | $3.49 | 22,921 | 04-15-2024 |
$3.61 | $3.58 | $3.61 | $3.95 | $3.58 | 75,652 | 04-12-2024 |
$3.58 | $3.69 | $3.58 | $3.69 | $3.56 | 14,708 | 04-11-2024 |
$3.56 | $3.55 | $3.56 | $3.6648 | $3.5 | 13,047 | 04-10-2024 |
$3.53 | $3.93 | $3.53 | $3.93 | $3.47 | 47,568 | 04-09-2024 |
$3.97 | $3.8 | $3.97 | $3.97 | $3.7701 | 13,359 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June PR Newswire CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO...
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1 , 2024 /PRNewswire/ -- Neur...